IDH1 and acute myeloid leukemia: IDH1- and IDH2-mutant primary AML cells are more sensitive to venetoclax compared with wildtype IDH1/2 cells78, with durable responses and encouraging OS seen in IDH-mutated patients treated with venetoclax regimens.